Myriad RBM Simoa Services

Ultrasensitive Immunoassays developed by Myriad RBM based on the Simoa™ technology

Unprecedented Sensitivity Backed by Myriad RBM's Immunoassay Service Quality

Quanterix’s single molecule array (Simoa™) technology provides ultrasensitive measurement of biomarkers, achieving orders-of-magnitude greater sensitivity than conventional immunoassay platforms. Utilizing our 15 years of assay development experience, Myriad RBM has developed high quality Simoa-based assays that are validated according to clinical laboratory standards. When levels of key protein biomarkers are extremely low in blood plasma or serum, Myriad RBM Simoa Services can quantify such biomarkers with high precision and unprecedented sensitivity to deliver an unparalleled approach to clinical research.

Myriad RBM will utilize our immunoassay development, manufacturing and validation expertise to expand the number and scope of our high quality, Simoa-based service menu. Currently, Myriad RBM Simoa Services consist of the following assays.

Simoa™ Services
(Serum and Plasma)
(Undiluted Samples)
Volume Required
Serum or plasmaOther fluids**
Amphiregulin (AR)0.24 pg/mL0.06 pg/mL100 µL150 µL
B Lymphocyte Chemoattractant (BLC, CXCL-13)0.64 pg/mL0.064 pg/mL50 µL150 µL
Granulocyte Colony-Stimulating Factor (G-CSF)0.59 pg/mL0.059 pg/mL50 µL150 µL
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)0.036 pg/mL0.009 pg/mL100 µL150 µL
Growth/differential factor 11 (GDF-11)5.00 pg/mL1.25 pg/mL100 µL150 µL
Interferon alpha (IFN-alpha)0.11 pg/mL0.055 pg/mL150 µL150 µL
Interferon beta (IFN-beta)0.16 pg/mL0.04 pg/mL100 µL150 µL
Interferon gamma (IFN-gamma)0.019 pg/mL0.0095 pg/mL150 µL150 µL
Interleukin-1 beta (IL-1 beta)0.031 pg/mL0.016 pg/mL150 µL150 µL
Interleukin-2 (IL-2)0.050 pg/mL0.025 pg/mL150 µL150 µL
Interleukin-5 (IL-5)0.052 pg/mL0.026 pg/mL150 µL150 µL
Interleukin-6 (IL-6)0.091 pg/mL0.0046 pg/mL50 µL150 µL
Interleukin-8 (IL-8)0.86 pg/mL0.0287 pg/mL50 µL150 µL
Interleukin-9 (IL-9)0.35 pg/mL0.0875 pg/mL100 µL150 µL
Interleukin-10 (IL-10)0.037 pg/mL0.0092 pg/mL100 µL150 µL
Interleukin-12 Subunit p40 (IL-12p40)7.30 pg/mL0.730 pg/mL50 µL150 µL
Interleukin-13 (IL-13)0.099 pg/mL0.005 pg/mL150 µL150 µL
Interleukin-17A (IL-17A)0.048 pg/mL0.012 pg/mL100 µL150 µL
Interleukin-17C (IL-17C)0.26 pg/mL0.13 pg/mL150 µL150 µL
Interleukin-31 (IL-31)0.024 pg/mL0.006 pg/mL100 µL150 µL
Kidney Injury Molecule-1 (KIM-1)3.10 pg/mL0.155 pg/mL50 µL150 µL
Oncostatin-M (OSM)0.14 pg/mL0.07 pg/mL150 µL150 µL
Oncostatin-M-Specific Receptor Subunit beta (OSMR)0.16 pg/mL0.0032 pg/mL50 µL150 µL
Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL)0.58 pg/mL0.145 pg/mL100 µL150 µL
Tumor Necrosis Factor-alpha (TNF-α)0.078 pg/mL0.020 pg/mL100 µL150 µL
Tumor Necrosis Factor Ligand Superfamily Member 14 (LIGHT free)1.5 pg/mL0.0075 pg/mL50 µL150 µL
Tumor Necrosis Factor Ligand Superfamily Member 14 Total (LIGHT Total)0.56 pg/mL0.14 pg/mL100 µL150 µL
Neurofilament Light Chain (NF-L)1.00 pg/mL0.25 pg/mL120 µL200 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.